17th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130101560 | USE OF ABO TYPE - The present invention relates to use of the ABO blood group genotype of an individual as a criterion for microbiota modulation that is tailored based on the differences in the spectrum of bacteria found between individuals with different ABO blood group genotypes. The present invention relates further to a microbial composition tailored based on the microbial genotypes shown to be specific for A, B, and/or O blood groups. | 2013-04-25 |
20130101561 | CLOSED SYSTEM SEPARATION OF ADHERENT BONE MARROW STEM CELLS FOR REGENERATIVE MEDICINE APPLICATIONS - A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described. | 2013-04-25 |
20130101562 | Methods for handling biological drugs containing living cells - The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about | 2013-04-25 |
20130101563 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 2013-04-25 |
20130101564 | METHOD FOR PREPARING DERMIS TISSUE CELLS AGGREGATION AND USES THEREOF - Dermis tissue cell aggregation, which comprises isolated dermis tissue cells with biological activity, is provided. The isolated dermis tissue cells are preserved in a mixed solution consisting of an isotonic saline solution for medical use, an anticoagulant, a nutrient for cells and a cell growth promoter, and a non-fluidity dermis tissue cell aggregation with adhesion is formed after several processes. A method for preparing the dermis tissue cell aggregation and the use thereof in preparing medicines for repairing scars are provided. | 2013-04-25 |
20130101565 | USE OF CARBONIC ANHYDRASE II FOR PRODUCING A DRUG - The present invention falls within the field of biomedicine. Specifically, the present invention relates to the use of carbonic anhydrase II for the manufacture of a medicament for the prevention and/or treatment of the damage caused by ischemia, ischemia followed by reperfusion or toxins, acute failure or rejection of a transplanted organ, preferably the kidney. In a preferred embodiment, the toxin is cisplatin. | 2013-04-25 |
20130101566 | PROBIOTIC COMPOSITION FOR USE IN THE TREATMENT OF BOWEL INFLAMMATION - The present disclosure is directed to compositions comprising | 2013-04-25 |
20130101567 | Methods to Expand a T Regulatory Cell Master Cell Bank - Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy. | 2013-04-25 |
20130101568 | IL-13 PRODUCING TR1-LIKE CELLS AND USE THEREOF - The present invention relates to an isolated Tr1-like cell population capable of producing IL-13, the population having immunosuppressive activities; methods for identifying/isolating/enriching the population and its uses thereof. | 2013-04-25 |
20130101569 | HAIR GROWTH STIMULANT - A composition of a mixture of vitamin and herbal supplements. Supplementation of the composition promotes hair growth and thickness by increasing the number of hairs and preventing hair loss. The concentration of the vitamin and herbal supplements in the composition is suitably about 0.01-100%. The composition may comprise a suitable carrier, solvent and/or emulgent. The composition may be, for example, an internally ingested tablet, a capsule, drops or a suspension. This formulation will enhance the hair thickness and provide elements for growing hair in humans and animals. | 2013-04-25 |
20130101570 | SERINE PROTEASE DERIVATIVES AND USES IN THE PREVENTION OR THE TREATMENT OF BLOOD COAGULATION DISORDERS - The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders. | 2013-04-25 |
20130101571 | ANTIDOTES FOR NITROBENZODIAZEPINES - Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants. | 2013-04-25 |
20130101572 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen. | 2013-04-25 |
20130101573 | DEGRADATION RESISTANT HSP70 FORMULATIONS AND USES THEREOF - The present invention relates to novel therapies that utilize stabilized exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of degradation resistant formulations of HSP70. Furthermore, the present invention is directed to methods comprising the administration of stabilized exogenous HSP70 for use in the treatment of HSP70 related disorders or conditions, for example, for increased endurance or alleviating fatigue syndrome | 2013-04-25 |
20130101574 | METHODS OF USING THROMBIN PEPTIDE DERIVATIVES - The present invention provides methods of reducing mortality in a subject exposed to a lethal dose of radiation, methods of reducing the risk of developing bacterial, fungal or viral systemic infection in a subject who is exposed or not exposed to radiation, methods of prevention and treatment of oral complications, particularly oral complications as a result of treatment with chemotherapy or radiation therapy, methods of treating dermal ulcers, particularly diabetic dermal ulcers, pressure dermal ulcers, venous stasis ulcers, and arterial ulcers, methods of promoting bone growth, and methods of promoting cartilage growth and repair in a subject in need thereof, by administering a thrombin peptide derivative to a subject. The administration may be local or systemic. | 2013-04-25 |
20130101575 | LACTOFERRIN SEQENCES, COMPOSITIONS AND METHODS FOR CORNEAL WOUND TREATMENT - The present invention relates to pharmaceutical compositions containing lactoferrin, or fragments of it, and their use in the treatment of wounds, particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C-lobe of lactoferrin, or functionally active fragments or variants thereof. | 2013-04-25 |
20130101576 | COMPOSITION CONTAINING AN EXTRACT OF A SEQUENTIAL OR SIMULTANEOUS FERMENTATION - Disclosed herein is a topical composition that contains a fermentation extract from a simultaneous or sequential fermentation. When topically applied to skin, the composition of the invention is effective in stimulating the production of hyaluronic acid, CD44 and Caspase 14 protein in skin cells. | 2013-04-25 |
20130101577 | Extended Soluble PH20 Polypeptides and uses thereof - Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof. | 2013-04-25 |
20130101578 | BIOMARKER FOR RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES - The invention provides kits and methods for the diagnosis, prognosis, and treatment of reduced kidney function in patients, such as diabetic patients. The methods include a step of detecting one or more nephrin degradation products in a sample from the subject, such as a urine sample. | 2013-04-25 |
20130101579 | METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD - The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein. | 2013-04-25 |
20130101580 | COMPOSITIONS AND METHODS FOR PROLONGING LIFESPAN - The present invention relates to therapeutic targets for aging. In particular, the present invention relates to the inhibition of the kynurenine pathway of tryptophan metabolism to extend lifespan or provide anti-aging benefits. | 2013-04-25 |
20130101581 | ANTIBODY CONSTANT REGION VARIANT - The present inventors carried out dedicated research to generate antibody constant regions with reduced Fcγ receptor-binding activity by altering amino acid sequences in the antibody constant region. As a result, the present inventors successfully identified novel constant region sequences with reduced Fcγ receptor-binding activity compared to conventional antibody constant regions. | 2013-04-25 |
20130101582 | Tiki1 and Tiki2, Wnt Inhibitors - This invention relates to Tiki1 and Tiki2 proteins and nucleic acids, cells expressing the same, and methods for identifying compounds that modulate Tiki1/2 activity for use in the treatment of osteoporosis or cellular proliferative disorders. | 2013-04-25 |
20130101583 | Etanercept Formulations Stabilized with Sodium Chloride - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2013-04-25 |
20130101584 | Etanercept Formulations Stabilized with Xylitol - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2013-04-25 |
20130101585 | METHOD OF INHIBITING OSTEOCLAST ACTIVITY - Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer. | 2013-04-25 |
20130101586 | STABLE MULTIPLE ANTIGEN-BINDING ANTIBODY - The invention provides antibodies that bind to multiple antigens, said antibodies having at least two antibody light chain variable domains and two antibody heavy chain variable domains, wherein each light chain variable domain is linked to a heavy chain variable domain to form a VH/VL construct, and wherein at least one of the VH domains comprises a particular amino acid at AHo position 12, 103 and/or 144, and at least one of the VL domains comprises a particular amino acid at AHo position 47 and/or 50. Nucleic acid molecules, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them, and the use of said antibodies in medicine are also disclosed. | 2013-04-25 |
20130101587 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 2013-04-25 |
20130101588 | NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS - The invention provides polypeptide, nucleic acid and other compositions. Polypeptide, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder, or reducing levels of LDL or oxLDL. | 2013-04-25 |
20130101589 | POLYPEPTIDES AND ANTIBODIES - Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide. | 2013-04-25 |
20130101590 | BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF - The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described. | 2013-04-25 |
20130101591 | METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN TYPE 1 PROTEIN - The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with | 2013-04-25 |
20130101592 | S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF - The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof. | 2013-04-25 |
20130101593 | ANTIBODIES THAT BIND HUMAN DENDRITIC AND EPITHELIAL CELL 205 (DEC-205) - Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 2013-04-25 |
20130101594 | ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies. | 2013-04-25 |
20130101595 | ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY - Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 2013-04-25 |
20130101596 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMIRA (Adalimumab). | 2013-04-25 |
20130101597 | MODULATION OF NK CELL ANTIGEN SPECIFIC EFFECTOR ACTIVITY BY MODULATION OF CXCR6 (CD186) - The instant invention is based, at least in part, on the discovery that CXCR6 plays a critical role in antigen-specific effector function of NK cells. Accordingly, the invention provides, among other things, methods for modulation of antigen-specific NK cell effector function, methods for identifying modulators of antigen-specific NK cell effector function. | 2013-04-25 |
20130101598 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. | 2013-04-25 |
20130101599 | BCMA-BASED STRATIFICATION AND THERAPY FOR MULTIPLE MYELOMA PATIENTS - The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided. | 2013-04-25 |
20130101600 | CXCL5 AS A MARKER OF HORMONE ESCAPE IN PROSTATE CANCER - The invention relates to the use of CXCL5 as a marker for assessing hormone escape in prostate cancer cells. The invention further provides diagnostic methods and kits for assessing hormone escape in prostate cancer cells, and CXCL5 antagonists for use in the treatment or prevention of prostate cancer and/or hormone escape in prostate cancer. | 2013-04-25 |
20130101601 | ANTIBODIES DIRECTED AGAINST NERVE GROWTH FACTOR (NGF) - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease. | 2013-04-25 |
20130101602 | Humanized Antibodies Against Human Interferon-Alpha - The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof. | 2013-04-25 |
20130101603 | BMP-ALK3 ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins. | 2013-04-25 |
20130101604 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease. | 2013-04-25 |
20130101605 | MODULATORS AND MODULATION OF THE INTERACTION BETWEEN RGM AND NEOGENIN - This invention relates to drug screening using mammalian repulsive guidance molecules and mammalian Neogenin. In addition, the invention provides for methods of preventing, alleviating or treating various disorders of the nervous system, angiogenic disorders or disorders of the cardio-vascular system and malignancies of different etiology by disrupting the interaction between RGM and Neogenin. | 2013-04-25 |
20130101606 | Novel Phosphorylation of Cardiac Troponin I as a Monitor for Cardiac Injury - This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention. | 2013-04-25 |
20130101607 | Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) Single Chain FV Antibody Fragment Conjugates and Methods of Use Thereof - Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided. | 2013-04-25 |
20130101608 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR - Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates. | 2013-04-25 |
20130101609 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES - In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same. | 2013-04-25 |
20130101610 | Therapeutic Uses of CD137 in Treating Autoimmune Disease - A method for treating or preventing a T-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble CD137 or CD137 | 2013-04-25 |
20130101611 | CITRULLINATION OF HUMAN PEPTIDYLARGININE DEIMINASE 4 (PAD-4) REGULATES ITS FUNCTION AND IMMUNOGENICITY - The present invention provides peptidylarginine deiminase 4 (PAD-4) polypeptides comprising one or more citrullinated Arginine sites. In one embodiment, a PAD-4 polypeptide comprises a citrulline residue at the following sites: Arg-205, Arg-212, Arg-218, Arg-372, Arg-374, Arg-383, Arg-394, Arg-495, Arg-536, and Arg-544. The present invention also provides methods for detecting the presence of autoantibodies to citrullinated PAD-4. The methods of the present invention may also be used to qualify Rheumatoid Arthritis status in a subject. In other embodiments, the present invention provides methods for inducing tolerance to citrullinated PAD-4. | 2013-04-25 |
20130101612 | VACCINE FOR ENVELOPED VIRUSES - The present invention provides a recombinant viral surface antigenic protein with enhanced stability. The present invention also provides a vaccine composition against enveloped viruses. | 2013-04-25 |
20130101613 | PROTECTIVE PROTEINS OF S. AGALACTIAE, COMBINATIONS THEREOF AND METHODS OF USING THE SAME - The invention relates to a composition comprising at least two protective proteins against | 2013-04-25 |
20130101614 | NOVEL LIVE RECOMBINANT BOOSTER VACCINE AGAINST TUBERCULOSIS - Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases. | 2013-04-25 |
20130101615 | METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS - This invention is a method for immunizing, preventing or treating a | 2013-04-25 |
20130101616 | COMPOSITIONS OF BOTANICAL EXTRACTS FOR CANCER THERAPY - Methods and compositions for prevention and therapy of cancer are provided. Compositions comprising therapeutically effective amounts of two or more of an extract of | 2013-04-25 |
20130101617 | ENV TRIMER IMMUNOGENS - Embodiments of the present invention are drawn to pure forms of human or simian immunodeficiency virus trimeric gp120/gp41 Env protein (Env trimers) and methods for making them. These embodiments address the need for an authentic immunogen lacking uncleaved gp160 Env protein and/or other forms of Env, such as gp41 “stumps” dissociated from gp120, which interfere with neutralizing antibody production in a vaccinated subject. | 2013-04-25 |
20130101618 | CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES - This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV). | 2013-04-25 |
20130101619 | RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLE DISEASE VIRUS ANTIGENS - The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines. | 2013-04-25 |
20130101620 | RECOMBINANT VARICELLA-ZOSTER VIRUS - A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence. | 2013-04-25 |
20130101621 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2013-04-25 |
20130101622 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS - The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s). | 2013-04-25 |
20130101623 | ATTENUATED MYCOBACTERIAL STRAIN AS NOVEL VACCINE AGAINST TUBERCULOSIS - The present invention provides a novel attenuated vaccine for tuberculosis. Furthermore, when used as a subcutaneous vaccine, the present invention induces a higher level of protection than the current vaccine. Finally, the present invention results in less tissue damage and a lower number of colony forming units (CFU) in the lungs compared to subjects vaccinated with BCG. | 2013-04-25 |
20130101624 | LINEAR IGE PEPTIDE EPITOPES OF HAZELNUT ALLERGEN COR A 1 AND CELERY ANTIGEN API 1 - Linear polypeptide epitopes of hazelnut cor a 1 and celery api 1.0101 allergen of a sequence length of ten to fifteen amino acids for treatment and prevention of hazelnut or celery allergy are provided. Means and methods for diagnosing hazelnut or celery allergy, and for detecting hazelnut or celery allergens in a sample, are also provided. | 2013-04-25 |
20130101625 | MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid. | 2013-04-25 |
20130101626 | MUCIN ANTIGEN VACCINE - Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector. | 2013-04-25 |
20130101627 | COMPOSITION WITH EXTRACTS FROM OLIVE LEAF, YARROW AND ROSEMARY FOR TREATING HUMAN DISEASES AND CONDITIONS - The present invention is a medical composition for treating a variety of human diseases and conditions. It comprises an effective amount of Olive Leaf extract, Yarrow extract and Rosemary extract as active components. Its inactive components include | 2013-04-25 |
20130101628 | NOVEL VEGF MIMETIC PEPTIDE-BASED SCAFFOLDS FOR THERAPEUTIC ANGIOGENESIS AND METHODS FOR THEIR USE - Disclosed herein is a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of vascular endothelial growth factor (VEGF), one of the most potent angiogenic signaling proteins. The VEGF-mimetic filaments disclosed herein were found to induce phosphorylation of VEGF receptors and induce pro-angiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival and migration in vitro. | 2013-04-25 |
20130101629 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF - The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies. | 2013-04-25 |
20130101630 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY - Provided herein is an impurity of varenicline, methylvarenicline, 6-methyl-5,8,14-triazatetracyclo[10.3.1.0 | 2013-04-25 |
20130101631 | METHOD AND APPARATUS FOR FORMING DELIVERY DEVICES FOR ORAL INTAKE OF AN AGENT - Provided are methods, systems and apparatuses for producing delivery devices, for example, for oral intake of an agent. The method can include assembling one or more layers including one or more materials with an agent or an agent-releasing formulation to form an intergraded device; folding the intergrated delivery device to form a folded integrated delivery device; and at least partially enclosing the folded delivery device to a form suitable for oral delivery. | 2013-04-25 |
20130101632 | NANOPARTICULATE FORMULATIONS OF MITHRAMYCIN OR MITHRAMYCIN ANALOGUES FOR TREATING CANCER - Methods and formulations for improving therapeutic potential of mithramycin (MTM) or MTM analogues are disclosed. For example, in certain aspects, methods for preparing a composition containing MTM or an MTM analogue nanoparticulate formulation and uses thereof are described. Furthermore, methods for delivering MTM or MTM analogues are disclosed. | 2013-04-25 |
20130101633 | ANTIMICROBIAL GELS - The present invention pertains to antimicrobial compositions comprising inter alia at least one alkenyl-and/or alkynyl-substituted polysiloxane, at least one polysiloxane comprising silicon-bonded hydrogen atoms, and at least one hydrosilylation catalyst, as well as antimicrobial silicone gels, wound dressings, and methods of preparing the above. | 2013-04-25 |
20130101634 | COMPOSITIONS AND METHODS FOR REDUCING MICROBIAL OVERGROWTH IN THE SMALL INTESTINES - An antimicrobial composition for reducing bacterial overgrowth in the small intestine is disclosed. The composition comprises a lytic enzyme combined with one or more anti-microbial essential oils, and a probiotic. Unlike broad spectrum antibiotics the disclosed composition does not enter the blood stream, does not destroy all intestinal microflora, and can be used on a continuing basis. | 2013-04-25 |
20130101635 | METHOD OF PREPARING SELF-ASSEMBLED EXTRACELLULAR MATRICES AND USE OF SELF-ASSEMBLED EXTRACELLULAR MATRICES FORMED BY USING THE METHOD - Methods of preparing a self-assembled matrix from cell-derived extracellular matrice, and of inducing cell proliferation and differentiation by using the self-assembled matrix, and applying the self-assembled matrix into cell therapy. In detail, unique extracellular matrices obtained from particular cells are collected and then subjected to decellularization in order to form a self-assembled matrix including nano fibers only formed of extracellular matrix. In addition, the matrix prepared as described above provides a platform that is effective for the induction of the mass proliferation or differentiation of cells, and thus, may be applied in manufacturing cell therapy products. | 2013-04-25 |
20130101636 | DIETARY SUPPLEMENTS WITH RAPID BUCCAL DISSOLUTION - There is provided a dietary supplement product comprising a sealed package containing a single dose of a dietary supplement, the dietary supplement including one or more active agents such as vitamins and mineral dispersed with a carrier so that it is in the form of a free-flowing, dry particulate which pours readily and dissolves rapidly on the tongue. | 2013-04-25 |
20130101637 | Bone Semi-Permeable Device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 2013-04-25 |
20130101638 | BONE SEMI-PERMEABLE DEVICE - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 2013-04-25 |
20130101639 | BONE SEMI-PERMEABLE DEVICE - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 2013-04-25 |
20130101640 | Etanercept Formulations Stabilized with Combinations of Sugars and Polyols - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2013-04-25 |
20130101641 | Periodontal Regeneration Composition and Method of Using Same - A periodontal structure regeneration composition for treatment of periodontal disease is a mixture of particles of a bone growth material and free collagen. All particles are sized to be less than 1 mm in diameter. The periodontal regeneration composition is injected into the periodontal pocket through an 18 gauge needle. The composition may contain a thickener that increases the viscosity of the composition after the material has been injected into the periodontal pocket. The composition is available in pre-filled syringes offered in a kit that may also contain strips of surgical sponge or gauze that are sized to fit within a periodontal pocket, a time of adhesive, a dental bur, a probe, a gauze placement tool, gauze counter and a brush for cleaning the dental bur. | 2013-04-25 |
20130101642 | METHODS AND COMPOSITIONS FOR TREATING ORAL MUCOSITIS - The present disclosure relates generally to the field of oral mucositis. More particularly, methods and compositions for treating, ameliorating and/or preventing oral mucositis are provided. Methods and compositions for treating, ameliorating and/or preventing oral mucositis are also provided. | 2013-04-25 |
20130101643 | METHODS AND COMPOSITIONS FOR MITIGATING PROCTITIS - The present disclosure relates generally to the field of proctitis. More particularly, methods and compositions for treating, ameliorating and/or preventing proctitis are provided. | 2013-04-25 |
20130101644 | TOCOTRIENOL COMPOSITIONS - Vitamin E compositions, methods of making such compositions and therapeutic uses of vitamin E compositions are disclosed. Compositions of matter comprising a tocotrienol making up at least 15 dry basis weight percent of the composition of matter and a constituent selected from a triglyceride and a triglyceride ester, wherein upon mixing of the composition of matter with water the tocotrienol based composition is substantially emulsified; and wherein upon mixing of the composition of matter with water a resulting emulsion has an intensity-weighed mean droplet size of less than 700 nm are also disclosed. | 2013-04-25 |
20130101645 | METHODS AND COMPOSITIONS FOR TREATING MUCOSITIS - The present disclosure relates generally to the field of mucositis. More particularly, methods and compositions for treating, ameliorating and/or preventing mucositis are provided by administering a clay to the subject in need. | 2013-04-25 |
20130101646 | Method of Producing Microparticles - A method of producing microparticles having a median diameter up to 100 μm and the microparticles so produced are described. The method includes the steps of providing a solvent having a bioactive dispersed or dissolved therein and a vehicle dissolved therein, carrying out an emulsification in a non-solvent phase to produce an emulsion containing the bioactive and the vehicle in a solvent phase, and evaporating the solvent to leave the microparticles, wherein a mixture of at least two surfactants is employed to stabilize the emulsion and wherein the mixture has a hydrophilic-lipophilic balance (HLB) of up to 8. | 2013-04-25 |
20130101647 | PHARMACEUTICAL COMPOSITION IN WHICH SOLUBILITY OF PARTIALLY SOLUBLE TRICYCLIC DERIVATIVE IS IMPROVED - A pharmaceutical composition includes lipid nanoparticles which include two or more of a phospholipid, cholesterol, and an ionic lipid, and a tricyclic derivative, wherein the solubility of the tricyclic derivative is improved. It is possible to solubilize a partially soluble tricyclic derivative in a high concentration even without using a solubilization aid harmful to the human body, to maintain improved solubility even if water is added for the use as an injection, and to show stability even if stored for a long time, by preparing lipid nanoparticles. Therefore, the lipid nanoparticles of the present invention can be used for preparing a pharmaceutical preparation containing a partially soluble tricyclic derivative as an active ingredient. | 2013-04-25 |
20130101648 | ASCOPHYLLUM NODOSUM ANIMAL CHEWS - An animal chew including a surface comprising a base composition, wherein the animal chew exhibits a hardness in the range of Shore 70A to Shore 70D as measured by ASTM D2240-05(2010) and a flexural modulus in the range of 50×10 | 2013-04-25 |
20130101649 | CONFECTIONERY PRODUCT CONTAINING ACTIVE AND/OR REACTIVE COMPONENTS AND METHODS OF PRODUCTION THEREOF - The invention relates to a confectionery product comprising an extruded body portion, the body portion having a plurality of capillaries disposed therein, one or more of the capillaries being at least partially filled with a fill material which is a different material from that of the extruded body portion, the fill material and optionally the body portion comprising various active and/or reactive components. Some embodiments are designed to provide sequential release profiles. The invention also relates to a process for the manufacture of the same. | 2013-04-25 |
20130101650 | USE OF DIHYDRODEHYDRODIISOEUGENOL AND PREPARATIONS COMPRISING DIHYDRODEHYDRODIISOEUGENOL - This invention relates to cosmetic and pharmaceutical preparations comprising
| 2013-04-25 |
20130101651 | DRIED FORMULATIONS OF NANOPARTICLE-COATED CAPSULES - A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation. | 2013-04-25 |
20130101652 | MULTILAYER FILMS FOR DELIVERY OF FLAVOR - An oral care composition having enhanced flavor release comprising an orally acceptable carrier containing a first flavor and a multilayer film for extended or delayed flavor release, the multilayer film including at least a center layer containing a second flavor, the center layer positioned between two outer surface layers, each surface layer including a release modulating agent, the first and second flavor being the same or different. The film is adapted to adhere to an oral cavity surface and the outer surface layers may comprise a mucoadhesive polymer, e.g. carboxy polymethylene, polycarbophil or polyvinyl pyrrolidone, and a film forming polymer, eg. hydroxypropylmethyl cellulose (HPMC). Suitable release modulating agents include HPMC and polyvinyl acetate. The carrier may be a toothpaste or mouthwash. | 2013-04-25 |
20130101653 | METHODS AND MATERIALS FOR REDUCING THE RISK OF INFECTIONS - This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures. | 2013-04-25 |
20130101654 | Silane Modified Diatomaceous Earth Mechanical Insecticide - A mechanical insecticide is made by mixing water with at least one type of silane to make a silane solution which is then mixed with diatomaceous earth until there is substantial deposition of the silane material on the diatomaceous earth material, to make a silanized diatomaceous earth. The silanized diatomaceous earth can be diluted with water and applied to vertical and overhead surfaces using a sprayer, for the control of insects. The silanized diatomaceous earth can also be dried into a powder for broadcast application, or mixed as a paste for brush/roller/caulk application. | 2013-04-25 |
20130101655 | CONTROL OF ARTHROPODS IN ANIMAL ENVIRONMENTS - A composite particle comprises i) an hydrophobic particle that adheres to the cuticle of one or more species of animal infesting arthropod; and ii) at least one organic chemical compound admixed therewith, wherein the said organic chemical is capable of controlling the population of at least one animal infesting arthropod species. Experiments proved the efficacy of the particle, for example in powder form, in relation to a variety of arthropods, for example red poultry mites. | 2013-04-25 |
20130101656 | IN SITU GELLING DRUG DELIVERY SYSTEM - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered. | 2013-04-25 |
20130101657 | ANGIOGENESIS INHIBITORS - Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject. | 2013-04-25 |
20130101658 | DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM - A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive. | 2013-04-25 |
20130101659 | CELL SHEET FOR MYOCARDIAL REGENERATION, METHOD OF PRODUCING THE SAME, AND METHOD OF USING THE SAME - Provided are a cell sheet and a three-dimensional structure thereof that include at least mesenchymal stem cells and myoblasts isolated from a cell culture support and that are to be applied to heart disease. Use of the cell sheet and the three-dimensional structure thereof including mesenchymal stem cells and myoblasts can notably improve cardiac functions compared with a conventional technology, i.e., use of cell sheets composed of myoblasts only or mesenchymal stem cells only. Furthermore, the cell sheet itself has high strength, and the transplantation procedure is also improved. | 2013-04-25 |